Innocare Pharma has dosed the first healthy volunteer in a clinical trial in China testing ICP-538, its oral treatment candidate for multiple sclerosis (MS) and other autoimmune diseases. The novel experimental therapy works by promoting the degradation of the VAV1 protein, essential for the function of T-cells and B-cells, which are immune cells that play […]
The post Trial of novel autoimmune disease treatment ICP-538 launches in China appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com